# POF Versus FOLFOX Plus IP Paclitaxel in AGC

> **NCT04155671** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 260 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** POF
- **DRUG:** FOLFOX plus PAC(ip)

## Key facts

- **NCT ID:** NCT04155671
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04155671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04155671, "POF Versus FOLFOX Plus IP Paclitaxel in AGC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04155671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*